Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Kitayama, Joji; Ishigami, Hironori; Yamaguchi, Hironori; Yamada, Jun; Soma, Daisuke; Miyato, Hideyo; Kamei, Takao; Lefor, Alan Kawarai; Sata, Naohiro

doi:10.1515/pp-2017-0002

Cited by 6 publications

(4 citation statements)

References 47 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2017, Kitayama et al [ 86 ] utilized a xenograft repetitive intraperitoneal model utilizing human gastric cancer cells. Fluorescein-conjugated paclitaxel was repetitively administered intraperitoneally, and the intratumour circulation of paclitaxel was assessed utilizing fluorescein microscopy.…”

Section: Paclitaxel: Nanomedicine-based Cancer Therapy—recent Advances and Challengesmentioning

confidence: 99%

Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Sharifi‐Rad

Quispe

Patra

et al. 2021

Oxidative Medicine and Cellular Longevity

105

View full text Add to dashboard Cite

Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.

show abstract

Section: Paclitaxel: Nanomedicine-based Cancer Therapy—recent Advances and Challengesmentioning

confidence: 99%

Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Sharifi‐Rad

Quispe

Patra

et al. 2021

Oxidative Medicine and Cellular Longevity

105

View full text Add to dashboard Cite

show abstract

“…Since PTX is highly lipophilic and poorly soluble in water, several new formulations have been investigated which can confer beneficial effects on its pharmacology and toxicology (Jiang et al, 2020;Kitayama et al, 2017;Yang et al, 2020). However, the components of an intravenous formulation may affect the clearance, protein binding and distribution of the drug.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy and safety of a new formulation‐lipid emulsion‐based PTX injection: Pharmacokinetics, tissue distributions and anticancer effect on human gastric cancer cells in vitro

Fei

Wang

et al. 2021

Biomedical Chromatography

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the most widely used chemotherapeutic agents. The commercial PTX formulation was based on Cremophor EL and ethanol owing to its poor aqueous solubility. However, Cremophor EL has been shown to cause toxic effects such as life-threatening anaphylaxis. In our study, we diluted PTX in a commercially available 20% (w/v) lipid emulsion (Lip-PTX) in order to avoid Cremophor EL. The purpose of this study was to evaluate the pharmacokinetics and tissue distributions between Lip-PTX and PTX injection. We also investigated the effects of Lip-PTX and PTX injection on human gastric cancer cells HGC-27 by MTT assay. The apoptosis was detected by flow cytometry with Annexin V/propidium iodide (PI) double staining. Furthermore, the safety such as acute toxicity was also assessed. The results showed that PTX in Sprague-Dawley rats administered Lip-PTX exhibited extended half-life, increased clearance (P < 0.05) and smaller area under the concentrationtime curve compared with PTX injection and there was little significant difference in the distribution of PTX in Sprague-Dawley rats or tumor-bearing mice between Lip-PTX and PTX injection. The cells treated with Lip-PTX had a higher percentage of apoptosis and a higher G 2 /M phase ratio, which indicated that the anticancer effect of Lip-PTX was significantly better than that of PTX injection. Moreover, our study highlighted the safety of Lip-PTX. This study demonstrated the feasibility and potential advantages of Lip-PTX for clinical therapy.

show abstract

“…The PMB entered the living mammalian cells cytoplasm within a few minutes without obvious disruption of the bilayer. Moreover, the solubility of anticancer drugs, e.g., paclitaxel (PTX), can be enhanced by using a PMB polymer as the cargo carrier. − There are also some reports in which a more complex blend of nanocomposite structures are developed. As an example, biodegradable blend films based on poly( l -lactide- co -caprolactone- co -glycolide) (PLCG) and PMB are prepared for use in a cardiovascular stent with regulated drug release behavior .…”

Section: Biomedical Applications Of Phospholipid Nanobiomaterialsmentioning

confidence: 99%

Emerging Phospholipid Nanobiomaterials for Biomedical Applications to Lab-on-a-Chip, Drug Delivery, and Cellular Engineering

Rahimnejad

Rabiee

Ahmadi

et al. 2021

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

The design of advanced nanobiomaterials to improve analytical accuracy and therapeutic efficacy has become an important prerequisite for the development of innovative nanomedicines. Recently, phospholipid nanobiomaterials including 2-methacryloyloxyethyl phosphorylcholine (MPC) have attracted great attention with remarkable characteristics such as resistance to nonspecific protein adsorption and cell adhesion for various biomedical applications. Despite many recent reports, there is a lack of comprehensive review on the phospholipid nanobiomaterials from synthesis to diagnostic and therapeutic applications. Here, we review the synthesis and characterization of phospholipid nanobiomaterials focusing on MPC polymers and highlight their attractive potentials for applications in micro/nanofabricated fluidic devices, biosensors, lab-on-a-chip, drug delivery systems (DDSs), COVID-19 potential usages for early diagnosis and even treatment, and artificial extracellular matrix scaffolds for cellular engineering.

show abstract

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Cited by 6 publications

References 47 publications

Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Evaluation of the efficacy and safety of a new formulation‐lipid emulsion‐based PTX injection: Pharmacokinetics, tissue distributions and anticancer effect on human gastric cancer cells in vitro

Emerging Phospholipid Nanobiomaterials for Biomedical Applications to Lab-on-a-Chip, Drug Delivery, and Cellular Engineering

Contact Info

Product

Resources

About